多替拉韦与达芦那韦方案在晚期HIV患者免疫重建中的随机对照试验
Advanz-4 试验为 IV 期开放标签随机研究,纳入 104 例 CD4+<100 cells/μL 的初治 HIV-1 成人,比较 3TC/ABC/DTG 与 3TC/ABC/DRV/r 方案。48 周 CD4+ 增幅两组无显著差异(p 0.2549),DTG 组病毒学抑制更快、炎症与细菌易位标志物下降更明显,且停药率更低。
要点
- CD4+<100 cells/μL 初治患者中 DTG 与 DRV/r 方案 48 周免疫重建无显著差异。
- DTG 组第 4 周和第 12 周病毒载量抑制显著优于 DRV/r 组。
- DTG 组炎症和细菌易位标志物下降幅度更大。
核心结论
- 在极晚期初治 HIV 患者中,DTG/3TC/ABC 安全有效,病毒学应答更快,且降低炎症和细菌易位标志物优于 DRV/r 方案。
研究设计与样本
- IV 期、1:1 随机、开放标签试验,纳入西班牙 9 家医院 104 例 CD4+<100 cells/μL 的初治 HIV-1 成人。
- 随机分为 3TC/ABC/DTG 组(n=52)和 3TC/ABC/DRV/r 组(n=52)。
- 主要终点为改良意向治疗人群第 48 周 CD4+ 绝对计数变化。
主要发现
- 48 周 CD4+ 中位增幅 DTG 组 206.5(154.4, 310.5)cells/μL,DRV/r 组 180.0(89.4, 314.0)cells/μL,p 0.2549。
- CD4+>200 cells/μL 比例 DTG 组 29 例(55.8%),DRV/r 组 21 例(42.9%),p 0.2343。
- 48 周病毒载量检测不到比例 DTG 组 41 例(78.8%),DRV/r 组 31 例(63.3%),p 0.1229;第 4 周 p<0.0001,第 12 周 p 0.0009。
- 48 周炎症标志物中位下降 DTG 组 -8(-11, -4)pg/mL vs DRV/r 组 -5(-9, -3)pg/mL,p 0.0357。
- 48 周细菌易位标志物中位下降 DTG 组 -972(-1334, -508)μg/mL vs DRV/r 组 -544(-1128, -292)μg/mL,p 0.0565。
关键数值与推荐
- CD4+<100 cells/μL 的初治 HIV-1 成人可考虑 DTG/3TC/ABC 方案,其病毒学抑制更快且炎症标志物改善更优。
临床怎么用
- 对极晚期 HIV 初治患者,DTG 方案可作为优先选择之一,尤其关注快速病毒学抑制和炎症控制。
局限性
- 开放标签设计,样本量较小(104 例),随访 48 周,部分比较未达统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The aim of this trial was to compare the immune reconstitution, virologic response, and safety of dolutegravir (DTG) vs. darunavir (DRV) boosted-based antiretroviral (ART) regimens in very advanced HIV patients. METHODS: Phase IV, randomized (1:1 ratio), open-label trial, including adult (≥18 years) ART-naïve HIV-1+ patients with CD4+ cell counts <100 cells/μL from nine hospitals in Spain. Participants were randomized to lamivudine (3TC)/abacavir (ABC)/DTG (DTG arm) and 3TC/ABC/DRV + ritonavir (DRV/r arm). PRIMARY ENDPOINT: change in the absolute CD4+ cell number at 48 weeks in the modified intention-to-treat population. TRIAL REGISTRATION: NCT02337322. RESULTS: In total, 104 patients (86.5% male, median (interquartile range [IQR]) age 41.0 (31.5, 47.0) years) were recruited and randomized to DTG (n = 52) and DRV/r arms (n = 52). Baseline median (IQR) CD4+ cell counts were 39.5 (16.0, 72.9) and 29.0 (8.0, 60.0) cells/μL in the DTG and DRV/r arms. They significantly increased by median (IQR) 206.5 (154.4, 310.5) and 180.0 (89.4, 314.0) cells/μL, respectively (p 0.2549); 29 (55.8%) and 21 (42.9%) (p 0.2343) patients, respectively, reached >200 cells/μL. Of the patients, 41 (78.8%) and 31 (63.3%) (p 0.1229) in the DTG and DRV/r arms, respectively, achieved undetectable viral loads at 48 weeks; differences were significant at weeks 4 (p < 0.0001) and 12 (p 0.0009). Inflammation and bacterial translocation markers decreased more in the DTG arm, median (IQR) -8 (-11, -4) vs. -5 (-9, -3) pg/mL (p 0.0357) and -972 (-1334, -508) vs. -544 (-1128, -292) μg/mL (p 0.0565), respectively, at 48 weeks. Discontinuation rates were higher in the DRV/r arm (3/52 (5.8%) vs. 9/51 (18.4%); p 0.0526). CONCLUSIONS: DTG/3TC/ABC is safe and efficacious in very advanced ART-naïve HIV + patients, induced a faster virologic response, and was superior to the DRV/r regimen in reducing inflammation and bacterial translocation markers at 48 weeks.
引用
- Miro JM, Torres F, Manzardo C, et al. Immune reconstitution in very advanced HIV patients treated with dolutegravir vs. darunavir-based triple antiretroviral therapy: the Advanz-4 randomized clinical trial. Clin Microbiol Infect. 2025. PMID: 41083105. doi:10.1016/j.cmi.2025.09.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。